Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carisbamate - SK Life Science

Next Previous
X
Search
Drug Profile

Carisbamate - SK Life Science

Alternative Names: Comfyde; JNJ-10234094; RWJ-333369; YKP-509

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK biopharmaceuticals; SK Life Science
  • Developer Janssen Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Johnson & Johnson Pharmaceutical Research & Development LLC; Ortho-McNeil Pharmaceutical; SK biopharmaceuticals; SK Life Science
  • Class Antiepileptic drugs; Carbamates; Chlorinated hydrocarbons; Neuroprotectants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Infantile spasms
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lennox-Gastaut syndrome
  • Discontinued Diabetic neuropathies; Epilepsy; Essential tremor; Migraine; Postherpetic neuralgia

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for phase-I development in Lennox-Gastaut-syndrome(In volunteers) in USA (PO, Suspension)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Lennox-Gastaut-syndrome(In volunteers) in USA (PO, Tablet)
  • 29 Jun 2022 SK Life Sciences completes phase I trial in Lennox-Gastaut syndrome in USA (PO) (NCT03731715)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top